BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com10-10

Revenue: $3,000 for Q2 2024, compared to $43,000 for Q2 2023. Expenses: Decreased by 53% quarter-over-quarter. Research and Development Expenses: $800,000 in Q2 2024, down from $2.3 million in Q2 2023...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474785054?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HywZe.sRwdFFg1.Cdt56qA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/60923920049f23264f07b5e44a14cc70","is_english":true,"pubTime":"2024-10-10 06:19","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474785054","market":"us","top_or_hot":-1,"title":"BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $3,000 for Q2 2024, compared to $43,000 for Q2 2023.\nExpenses: Decreased by 53% quarter-over-quarter.\nResearch and Development Expenses: $800,000 in Q2 2024, down from $2.3 million in Q2 2023...</p>\n\n<a href=\"https://finance.yahoo.com/news/biocardia-inc-bcda-q2-2024-221935335.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 06:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biocardia-inc-bcda-q2-2024-221935335.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $3,000 for Q2 2024, compared to $43,000 for Q2 2023.\nExpenses: Decreased by 53% quarter-over-quarter.\nResearch and Development Expenses: $800,000 in Q2 2024, down from $2.3 million in Q2 2023...</p>\n\n<a href=\"https://finance.yahoo.com/news/biocardia-inc-bcda-q2-2024-221935335.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCDA","symbol_name":"BioCardia","start_time":0,"source_url":"https://finance.yahoo.com/news/biocardia-inc-bcda-q2-2024-221935335.html","article_id":"2474785054","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HywZe.sRwdFFg1.Cdt56qA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/60923920049f23264f07b5e44a14cc70"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474785054","pubTimestamp":1728512375,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $3,000 for Q2 2024, compared to $43,000 for Q2 2023.Research and Development Expenses: $800,000 in Q2 2024, down from $2.3 million in Q2 2023.Selling, General and Administrative Expenses: $852,000 in Q2 2024, down from $1.2 million in Q2 2023.Net Loss: $1.6 million for Q2 2024, reduced from $3.4 million in Q2 2023.Cash Used in Operations: $1.4 million in Q2 2024, down from $3.2 million in Q2 2023.GuruFocus has detected 6 Warning Signs with BCDA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.The CardiAMP Heart Failure II trial is the only confirmatory pivotal trial of a cell therapy in heart failure, with a high statistical probability of success based on interim results.BioCardia Inc  has submitted an FDA application for market clearance of the Morph DNA Steerable Introducers, which could enhance revenue generation and partnering interests.Revenues for the second quarter of 2024 were significantly lower compared to the same ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BCDA":"BioCardia","BCDAW":"BIOCARDIA INC"},"translate_title":"BioCardia Inc(BCDA)2024年第二季度收益看涨期权亮点：财务挑战中的战略进步","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCDA":1,"BCDAW":0.9},"content_text":"Revenue: $3,000 for Q2 2024, compared to $43,000 for Q2 2023.\nExpenses: Decreased by 53% quarter-over-quarter.\nResearch and Development Expenses: $800,000 in Q2 2024, down from $2.3 million in Q2 2023.\nSelling, General and Administrative Expenses: $852,000 in Q2 2024, down from $1.2 million in Q2 2023.\nNet Loss: $1.6 million for Q2 2024, reduced from $3.4 million in Q2 2023.\nCash Used in Operations: $1.4 million in Q2 2024, down from $3.2 million in Q2 2023.\n\n\nWarning! GuruFocus has detected 6 Warning Signs with BCDA.\n\nRelease Date: August 13, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nBioCardia Inc (NASDAQ:BCDA) reported positive interim results from the CardiAMP Heart Failure I trial, showing improved survival, reduced major adverse cardiac events, and enhanced quality of life for patients.\nThe CardiAMP Heart Failure II trial is the only confirmatory pivotal trial of a cell therapy in heart failure, with a high statistical probability of success based on interim results.\nBioCardia Inc (NASDAQ:BCDA) has expanded its Executive Steering Committee with two additional world-class heart failure clinicians, enhancing the trial's credibility and support.\nThe company has made significant progress in other programs, including the CardiAMP cell therapy for chronic myocardial ischemia and a partnership with CellProthera for acute myocardial infarction.\nBioCardia Inc (NASDAQ:BCDA) has submitted an FDA application for market clearance of the Morph DNA Steerable Introducers, which could enhance revenue generation and partnering interests.\n\n Negative Points \n\nBioCardia Inc (NASDAQ:BCDA) experienced a tough quarter for its share price, despite delivering on business milestones.\nRevenues for the second quarter of 2024 were significantly lower compared to the same period in 2023, indicating financial challenges.\nThe company reported a net loss of $1.6 million for the second quarter of 2024, although this was an improvement from the previous year.\nBioCardia Inc (NASDAQ:BCDA) is exploring pathways to secure funding to meet Nasdaq listing requirements, which may involve potential dilution for current shareholders.\nThere is uncertainty regarding the approval timeline for CardiAMP in Japan, as the company awaits final data from the CardiAMP Heart Failure I trial.\n\n Q & A Highlights \nQ: How is the data from the CardiAMP Heart Failure I trial influencing enrollment for the CardiAMP Heart Failure II study? A: Peter Altman, President and CEO, explained that the positive data from Heart Failure I, showing improved survival and reduced major adverse cardiac events, is significantly aiding enrollment for Heart Failure II. The compelling safety and efficacy data, particularly the 86% relative risk reduction in mortality for the NTproBNP population, is a strong incentive for physicians to enroll patients in the trial.\nQ: Can you discuss any streamlining efforts already in place for the CardiAMP Heart Failure II trial? A: Peter Altman noted that the trial design has been streamlined by allowing certain follow-up visits to be conducted via phone, reducing the burden on clinical sites and costs for BioCardia. This streamlining is expected to make the trial more efficient and less expensive.\nQ: What is the expected gender ratio for the CardiAMP Heart Failure II trial, given the male-dominated enrollment in Heart Failure I? A: Peter Altman acknowledged the challenge of gender imbalance in heart failure research and expressed a desire to achieve a more balanced enrollment in Heart Failure II. He hopes the compelling safety data will encourage more female participation, although achieving a 50% ratio may be challenging.\nQ: What is the status of the CardiAMP submission for approval in Japan, and is approval expected next year? A: Peter Altman stated that BioCardia is in a good position to submit for approval in Japan, pending final data from the CardiAMP Heart Failure I trial. The company is optimistic about approval due to the extensive patient data and existing approvals for related technologies in Japan.\nQ: How is BioCardia planning to comply with Nasdaq listing requirements, and will this affect current shareholders? A: Peter Altman explained that BioCardia is exploring funding options to meet Nasdaq's requirements, including maintaining a share price above $1 and meeting equity or market capitalization thresholds. The company is mindful of potential dilution but is focused on advancing its business and achieving significant milestones.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474785054"}